SCHEMBL3457700

SCHEMBL3457700

Fc1cccc(CCc2cc(Cl)c3ccccc3n2)c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
APP P05067 2/20 0.46
PLA2G2A P14555 2/20 0.44
MAOB P27338 1/20 0.43
CCNE2 O96020 1/20 0.43
CCNE1 P24864 1/20 0.43
CDK2 P24941 1/20 0.43
LMNA P02545 2/20 0.43
MAPT P10636 2/20 0.43
GBA1 P04062 2/20 0.42
TAAR1 Q96RJ0 3/20 0.42
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41
TP53 P04637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
KCNH2 Q12809 1/20 0.40
KDM4E B2RXH2 1/20 0.39
NT5E P21589 1/20 0.39
ADORA2A P29274 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29219438 0.87 KCNH2 (0.48) APPPLA2G2AMAOBKCNH2KDM4E
SCHEMBL3457284 0.86 APP (0.48) APPPLA2G2AMAOBMAPTTAAR1
SCHEMBL3457404 0.86 PLA2G2A (0.46) APPPLA2G2AMAOBLMNAMAPT
SCHEMBL3456550 0.83 PLA2G2A (0.39) APPPLA2G2AMAOBMAPTL3MBTL1
SCHEMBL3457066 0.80 L3MBTL1 (0.44) PLA2G2ALMNAMAPTTP53L3MBTL1
SCHEMBL3457738 0.77 KDM4E (0.42) MAOBLMNAMAPTTAAR1TP53
SCHEMBL29219366 0.77 ALDH1A1 (0.46) APPMAOBLMNAMAPTL3MBTL1
SCHEMBL3456970 0.77 CXCR2 (0.41) MAOBLMNAMAPTTP53L3MBTL1
SCHEMBL14352265 0.74 MAOA (0.42) MAOBLMNAMAPTTAAR1TP53
SCHEMBL14128989 0.74 KDM4E (0.60) MAOBLMNAMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2258688-B1 Pyridinone derivatives for treatment of atherosclerosis SMITHKLINE BEECHAM LTD (GB) 2012-11-21 EP disclosed
EP-2258688-A1 Pyridinone derivatives for treatment of atherosclerosis SmithKline Beecham Limited (GB) 2010-12-08 EP disclosed
US-7235566-B2 Pyridinone derivatives for treatment of atherosclerosis SMITHKLINE BEECHAM P.L.C. (GB) 2007-06-26 US disclosed
US-7235566-B2 Pyridinone derivatives for treatment of atherosclerosis SMITHKLINE BEECHAM P.L.C. (GB) 2007-06-26 US disclosed
US-7235566-B2 Pyridinone derivatives for treatment of atherosclerosis SMITHKLINE BEECHAM P.L.C. (GB) 2007-06-26 US disclosed
US-20050014793-A1 Pyridinone derivatives for treatment of atherosclerosis GLAXO GROUP LIMITED (GB) 2005-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014793-A1 Pyridinone derivatives for treatment of atherosclerosis PNPO, PLA2G7, PLA2G4B APP 1543/4885PLA2G2A 30/4885MAOB 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.